nach oben

Erschienen in:

Open Access 01.09.2011 | Article

Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet

verfasst von: P. M. Jamieson, M. E. Cleasby, Y. Kuperman, N. M. Morton, P. A. T. Kelly, D. G. Brownstein, K. J. Mustard, J. M. Vaughan, R. N. Carter, C. N. Hahn, D. G. Hardie, J. R. Seckl, A. Chen, W. W. Vale

Erschienen in: Diabetologia | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Urocortins are the endogenous ligands for the corticotropin-releasing factor receptor type 2 (CRFR2), which is implicated in regulating energy balance and/or glucose metabolism. We determined the effects of chronic CRFR2 activation on metabolism in vivo, by generating and phenotyping transgenic mice overproducing the specific CRFR2 ligand urocortin 3.

Methods

Body composition, glucose metabolism, insulin sensitivity, energy efficiency and expression of key metabolic genes were assessed in adult male urocortin 3 transgenic mice (Ucn3 ⁺) under control conditions and following an obesogenic high-fat diet (HFD) challenge.

Results

Ucn3⁺ mice had increased skeletal muscle mass with myocyte hypertrophy. Accelerated peripheral glucose disposal, increased respiratory exchange ratio and hypoglycaemia on fasting demonstrated increased carbohydrate metabolism. Insulin tolerance and indices of insulin-stimulated signalling were unchanged, indicating these effects were not mediated by increased insulin sensitivity. Expression of the transgene in Crfr2 (also known as Crhr2)-null mice negated key aspects of the Ucn3⁺ phenotype. Ucn3⁺ mice were protected from the HFD-induced hyperglycaemia and increased adiposity seen in control mice despite consuming more energy. Expression of uncoupling proteins 2 and 3 was higher in Ucn3⁺ muscle, suggesting increased catabolic processes. IGF-1 abundance was upregulated in Ucn3⁺ muscle, providing a potential paracrine mechanism in which urocortin 3 acts upon CRFR2 to link the altered metabolism and muscular hypertrophy observed.

Conclusions/interpretation

Urocortin 3 acting on CRFR2 in skeletal muscle of Ucn3 ⁺ mice results in a novel metabolically favourable phenotype, with lean body composition and protection against diet-induced obesity and hyperglycaemia. Urocortins and CRFR2 may be of interest as potential therapeutic targets for obesity.

Nur mit Berechtigung zugänglich

Lovenberg TW, Liaw CW, Grigoriadis DE et al (1995) Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 92:836–840PubMedCrossRef

Vaughan JM, Donaldson C, Bittencourt J et al (1995) Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378:287–292PubMedCrossRef

Reyes TM, Lewis K, Perrin MH et al (2001) Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98:2843–2848PubMedCrossRef

Lewis K, Li C, Perrin MH et al (2001) Identification of Urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98:7570–7575PubMedCrossRef

Hsu SY, Hsueh AJ (2001) Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7:605–611PubMedCrossRef

Reul JM, Holsboer F (2002) Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2:23–33PubMedCrossRef

Broberger C (2005) Brain regulation of food intake and appetite: molecules and networks. J Intern Med 258:301–327PubMedCrossRef

Black PH (2006) The inflammatory consequences of psychologic stress: relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II. Med Hypotheses 67:879–891PubMedCrossRef

Bale TL, Anderson KR, Roberts A, Lee K-F, Nagy TR, Vale WW (2003) Corticotropin-releasing factor receptor-2 deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold. Endocrinology 144:2580–2587PubMedCrossRef

10.

Carlin KM, Vale WW, Bale TL (2006) Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis. Proc Natl Acad Sci USA 103:3462–3467PubMedCrossRef

11.

Chen A, Brar B, Choi CS et al (2006) Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc Natl Acad Sci USA 103:16580–16585PubMedCrossRef

12.

Li C, Chen P, Vaughan J et al (2003) Urocortin III is expressed in pancreatic beta-cells and stimulates insulin and glucagon secretion. Endocrinology 144:3216–3224PubMedCrossRef

13.

Solinas G, Summermatter S, Mainieri D et al (2006) Corticotropin-releasing hormone directly stimulates thermogenesis in skeletal muscle possibly through substrate cycling between de novo lipogenesis and lipid oxidation. Endocrinology 147:31–38PubMedCrossRef

14.

Li C, Chen P, Vaughan J, Lee KF, Vale W (2007) Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. Proc Natl Acad Sci USA 104:4206–4211PubMedCrossRef

15.

Bale TL, Contarino A, Smith GW et al (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Gen 24:410–414CrossRef

16.

Nagy TR, Clair AL (2000) Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. Obes Res 8:392–398PubMedCrossRef

17.

Brooke MH, Kaiser KK (1970) Muscle fiber types: how many and what kind? Arch Neurol 23:369–379PubMed

18.

Sokoloff L, Reivich M, Kennedy C et al (1977) The [¹⁴C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897–916PubMedCrossRef

19.

Cleasby ME, Davey JR, Reinten TA et al (2005) Acute bidirectional manipulation of muscle glucose uptake by in vivo electrotransfer of constructs targeting glucose transporter genes. Diabetes 54:2702–2711PubMedCrossRef

20.

Chan TM, Exton JH (1976) A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal Biochem 71:96–105PubMedCrossRef

21.

Kim HJ, Higashimori T, Park SY et al (2004) Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060–1067PubMedCrossRef

22.

Jamieson PM, Nyirenda MJ, Walker BR, Chapman KE, Seckl JR (1999) Interactions between oestradiol and glucocorticoid regulatory effects on liver-specific glucocorticoid-inducible genes: possible evidence for a role of hepatic 11beta-hydroxysteroid dehydrogenase type 1. J Endocrinol 160:103–109PubMedCrossRef

23.

Jamieson PM, Chapman KE, Edwards CR, Seckl JR (1995) 11 beta-Hydroxysteroid dehydrogenase is an exclusive 11 beta-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 136:4754–4761PubMedCrossRef

24.

Richter EA, Ruderman NB (2009) AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J 418:261–275PubMedCrossRef

25.

Livesey G, Elia M (1988) Estimation of energy expenditure, net carbohydrate utilization, and net fat oxidation and synthesis by indirect calorimetry: evaluation of errors with special reference to the detailed composition of fuels. Am J Clin Nutr 47:608–628PubMed

26.

Bezaire V, Seifert EL, Harper ME (2007) Uncoupling protein-3: clues in an ongoing mitochondrial mystery. FASEB J 21:312–324PubMedCrossRef

27.

Brand MD, Esteves TC (2005) Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab 2:85–93PubMedCrossRef

28.

Bezaire V, Spriet LL, Campbell S et al (2005) Constitutive UCP3 overexpression at physiological levels increases mouse skeletal muscle capacity for fatty acid transport and oxidation. FASEB J 19:977–979PubMed

29.

Li B, Nolte LA, Ju JS et al (2000) Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice. Nat Med 6:1115–1120PubMedCrossRef

30.

Tsuboyama-Kasaoka N, Tsunoda N, Maruyama K et al (1999) Overexpression of GLUT4 in mice causes up-regulation of UCP3 mRNA in skeletal muscle. Biochem Biophys Res Commun 258:187–193PubMedCrossRef

31.

Dilger AC, Spurlock ME, Grant AL, Gerrard DE (2010) Myostatin null mice respond differently to dietary-induced and genetic obesity. Anim Sci J 81:586–593PubMedCrossRef

32.

Schmitz F, Hartmann H, Stumpel F, Creutzfeldt W (1991) In vivo metabolic action of insulin-like growth factor I in adult rats. Diabetologia 34:144–149PubMedCrossRef

33.

Dimitriadis G, Parry-Billings M, Bevan S et al (1992) Effects of insulin-like growth factor I on the rates of glucose transport and utilization in rat skeletal muscle in vitro. Biochem J 285(Pt 1):269–274PubMed

34.

Di Cola G, Cool MH, Accili D (1997) Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest 99:2538–2544PubMedCrossRef

35.

Semsarian C, Wu MJ, Ju YK et al (1999) Skeletal muscle hypertrophy is mediated by a Ca²⁺-dependent calcineurin signalling pathway. Nature 400:576–581PubMedCrossRef

36.

LeBrasseur NK, Walsh K, Arany Z (2011) Metabolic benefits of resistance training and fast glycolytic skeletal muscle. Am J Physiol Endocrinol Metab 300:E3–E10PubMedCrossRef

37.

Morrow LA, O’Brien MB, Moller DE, Flier JS, Moses AC (1994) Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 79:205–210PubMedCrossRef

38.

Palazzolo I, Stack C, Kong L et al (2009) Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 63:316–328PubMedCrossRef

39.

Holmberg BJ, Morrison CD, Keisler DH (2001) Endocrine responses of ovariectomized ewes to i.c.v. infusion of urocortin. J Endocrinol 171:517–524PubMedCrossRef

40.

Quaife CJ, Mathews LS, Pinkert CA, Hammer RE, Brinster RL, Palmiter RD (1989) Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology 124:40–48PubMedCrossRef

41.

Mathews LS, Hammer RE, Behringer RR et al (1988) Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 123:2827–2833PubMedCrossRef

42.

Coleman ME, DeMayo F, Yin KC et al (1995) Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 270:12109–12116PubMedCrossRef

43.

Musaro A, McCullagh K, Paul A et al (2001) Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27:195–200PubMedCrossRef

44.

Argiles JM, Figueras M, Ametller E et al (2008) Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle Nerve 37:190–195PubMedCrossRef

45.

Hinkle RT, Donnelly E, Cody DB, Bauer MB, Sheldon RJ, Isfort RJ (2004) Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force. J Muscle Res Cell Motil 25:539–547PubMedCrossRef

46.

Hinkle RT, Donnelly E, Cody DB et al (2003) Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions. Am J Physiol Endocrinol Metab 285:E889–E898PubMed

47.

Shavlakadze T, Winn N, Rosenthal N, Grounds MD (2005) Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm IGF Res 15:4–18PubMedCrossRef

48.

Moses AC, Young SC, Morrow LA, O’Brien M, Clemmons DR (1996) Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45:91–100PubMedCrossRef

49.

Pennisi P, Gavrilova O, Setser-Portas J et al (2006) Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147:2619–2630PubMedCrossRef

50.

Wang J, Xu Y, Zhu H, Zhang R, Zhang G, Li S (2008) Urocortin’s inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 26:359–368PubMedCrossRef

Titel: Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet
verfasst von: P. M. Jamieson
M. E. Cleasby
Y. Kuperman
N. M. Morton
P. A. T. Kelly
D. G. Brownstein
K. J. Mustard
J. M. Vaughan
R. N. Carter
C. N. Hahn
D. G. Hardie
J. R. Seckl
A. Chen
W. W. Vale
Publikationsdatum: 01.09.2011
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 9/2011
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-011-2205-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2011

Leptin administered in physiological or pharmacological doses does not regulate circulating angiogenesis factors in humans

New approaches for the evaluation of renal vascular function in diabetes

Generation of pancreatic insulin-producing cells from rhesus monkey induced pluripotent stem cells

Could there be a role for metformin in type 1 and type 2 diabetic pregnancies?

How can we realise the potentially large public health benefit of screening for type 2 diabetes mellitus in south Asians?